-
Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study. Blood. 2024 Feb 29; 143(9):796-806.
Leavitt AD, Konkle BA, Stine KC, Visweshwar N, Harrington TJ, Giermasz A, Arkin S, Fang A, Plonski F, Yver A, Ganne F, Agathon D, Resa MLA, Tseng LJ, Di Russo G, Cockroft BM, Cao L, Rupon J. PMID: 37871576.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy. Blood Adv. 2023 10 10; 7(19):5671-5679.
von Drygalski A, Gomez E, Giermasz A, Castaman G, Key NS, Lattimore SU, Leebeek FWG, Miesbach WA, Recht M, Gut R, Dolmetsch R, Monahan PE, Le Quellec S, Pipe SW. PMID: 36490302; PMCID: PMC10539871.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCells
-
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. J Thromb Haemost. 2023 12; 21(12):3450-3462.
O'Mahony B, Dunn AL, Leavitt AD, Peyvandi F, Ozelo MC, Mahlangu J, Peerlinck K, Wang JD, Lowe GC, Tan CW, Giermasz A, Tran H, Khoo TL, Cockrell E, Pepperell D, Chambost H, López Fernández MF, Kazmi R, Majerus E, Skinner MW, Klamroth R, Quinn J, Yu H, Wong WY, Robinson TM, Pipe SW. PMID: 37678546.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022 03 17; 386(11):1013-1025.
Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, Symington E, Quon DV, Wang JD, Peerlinck K, Pipe SW, Madan B, Key NS, Pierce GF, O'Mahony B, Kaczmarek R, Henshaw J, Lawal A, Jayaram K, Huang M, Yang X, Wong WY, Kim B, GENEr8-1 Trial Group. PMID: 35294811.
View in:
PubMed Mentions:
54 Fields:
Translation:
HumansCellsCTClinical Trials
-
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021 Nov; 27(6):911-920.
Escobar M, Luck J, Averianov Y, Ducore J, Fernández MFL, Giermasz A, Hart DP, Journeycake J, Kessler C, Leissinger C, Mahlangu J, Martinez LV, Miesbach W, Mitha IH, Quon D, Reding MT, Schved JF, Stasyshyn O, Vilchevska KV, Wang M, Windyga J, Alexander WA, Al-Sabbagh A, Bonzo D, Mitchell IS, Wilkinson TA, Hermans C. PMID: 34614267; PMCID: PMC9292306.
View in:
PubMed Mentions:
4 Fields:
Translation:
HumansCTClinical Trials
-
Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy. Blood. 2020 11 26; 136(22):2524-2534.
Rosen S, Tiefenbacher S, Robinson M, Huang M, Srimani J, Mackenzie D, Christianson T, Pasi KJ, Rangarajan S, Symington E, Giermasz A, Pierce GF, Kim B, Zoog SJ, Vettermann C. PMID: 32915950; PMCID: PMC7714098.
View in:
PubMed Mentions:
27 Fields:
Translation:
HumansCellsCTClinical Trials
-
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019 11 12; 3(21):3241-3247.
Von Drygalski A, Giermasz A, Castaman G, Key NS, Lattimore S, Leebeek FWG, Miesbach W, Recht M, Long A, Gut R, Sawyer EK, Pipe SW. PMID: 31698454; PMCID: PMC6855101.
View in:
PubMed Mentions:
32 Fields:
-
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med. 2017 12 07; 377(23):2215-2227.
George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. PMID: 29211678; PMCID: PMC6029626.
View in:
PubMed Mentions:
309 Fields:
Translation:
HumansCellsCTClinical Trials
-
A gap in comprehensive care: Sexual health in men with haemophilia. Haemophilia. 2017 07; 23(4):e389-e391.
Tobase P, Mahajan A, Francis D, Leavitt AD, Giermasz A. PMID: 28574623.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017 Jan; 23(1):67-76.
Escobar MA, Tehranchi R, Karim FA, Caliskan U, Chowdary P, Colberg T, Giangrande P, Giermasz A, Mancuso ME, Serban M, Tsay W, Mahlangu JN. PMID: 27480487.
View in:
PubMed Mentions:
12 Fields:
Translation:
Humans
-
Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine. Vaccine. 2012 Mar 30; 30(16):2633-9.
Kono M, Nakamura Y, Suda T, Uchijima M, Tsujimura K, Nagata T, Giermasz AS, Kalinski P, Nakamura H, Chida K. PMID: 22365841.
View in:
PubMed Mentions:
17 Fields:
Translation:
AnimalsCellsPHPublic Health
-
Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother. 2009 Aug; 58(8):1329-36.
Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, Kalinski P. PMID: 19156413; PMCID: PMC2907477.
View in:
PubMed Mentions:
34 Fields:
Translation:
HumansAnimalsCells
-
Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res. 2007 Oct 15; 67(20):10012-8.
Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, Hendricks RL, Kalinski P. PMID: 17942935; PMCID: PMC2905256.
View in:
PubMed Mentions:
18 Fields:
Translation:
AnimalsCells
-
Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res. 2006; 36(1-3):137-46.
Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB. PMID: 17337774.
View in:
PubMed Mentions:
30 Fields:
Translation:
HumansAnimalsCells
-
Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther. 2005 Oct; 5(10):1303-15.
Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB. PMID: 16197336.
View in:
PubMed Mentions:
47 Fields:
Translation:
HumansAnimalsCells
-
Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol. 2005 Feb; 42(4):535-9.
Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB. PMID: 15607810.
View in:
PubMed Mentions:
42 Fields:
Translation:
HumansCells
-
Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor. Apoptosis. 2004 Mar; 9(2):193-204.
Stoklosa T, Golab J, Wójcik C, Wlodarski P, Jalili A, Januszko P, Giermasz A, Wilczynski GM, Pleban E, Marczak M, Wilk S, Jakóbisiak M. PMID: 15004516.
View in:
PubMed Mentions: Fields:
Translation:
Animals
-
Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol. 2003 Sep 01; 171(5):2366-73.
Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P. PMID: 12928383.
View in:
PubMed Mentions:
142 Fields:
Translation:
HumansCells
-
Type-1 polarized nature of mouse liver CD8alpha- and CD8alpha+ dendritic cells: tissue-dependent differences offset CD8alpha-related dendritic cell heterogeneity. Eur J Immunol. 2003 Jul; 33(7):2007-13.
O'Connell PJ, Son YI, Giermasz A, Wang Z, Logar AJ, Thomson AW, Kalinski P. PMID: 12884867.
View in:
PubMed Mentions:
10 Fields:
Translation:
AnimalsCells
-
A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma with a low apoptotic index. Oncol Rep. 2002 Sep-Oct; 9(5):991-4.
Jalili A, Stoklosa T, Giermasz A, Olszewska D, Wilczynski G, Jakobisiak M, Golab J. PMID: 12168061.
View in:
PubMed Mentions:
1 Fields:
Translation:
AnimalsCells
-
Augmented antitumour effects of combination therapy with TNP-470 and chemoimmunotherapy in mice. J Cancer Res Clin Oncol. 2002 Aug; 128(8):433-42.
Dabrowska-Iwanicka A, Olszewska D, Jalili A, Makowski M, Grzela T, Marczak M, Hoser G, Giermasz A, Golab J, Jakóbisiak M. PMID: 12200600.
View in:
PubMed Mentions:
2 Fields:
Translation:
Animals
-
Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol Rep. 2002 Jul-Aug; 9(4):879-85.
Feleszko W, Jalili A, Olszewska D, Mlynarczuk I, Grzela T, Giermasz A, Jakóbisiak M. PMID: 12066226.
View in:
PubMed Mentions:
3 Fields:
Translation:
HumansAnimalsCells
-
IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells. Oncol Rep. 2002 Mar-Apr; 9(2):427-31.
Kozar K, Kaminski R, Giermasz A, Basak G, Zagozdzon R, Rybczynska J, Wasik M, Lasek W, Jakobisiak M, Golab J. PMID: 11836621.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansAnimalsCells
-
Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. Int J Cancer. 2002 Feb 20; 97(6):746-50.
Giermasz A, Makowski M, Kozlowska E, Nowis D, Maj M, Jalili A, Feleszko W, Wójcik C, Dabrowska A, Jakóbisiak M, Golab J. PMID: 11857349.
View in:
PubMed Mentions:
4 Fields:
Translation:
Animals
-
Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. Oncol Rep. 2002 Jan-Feb; 9(1):199-203.
Giermasz A, Makowski M, Nowis D, Jalili A, Maj M, Dabrowska A, Czajka A, Jakobisiak M, Golab J. PMID: 11748483.
View in:
PubMed Mentions: Fields:
Translation:
Animals
-
Butyric acid enhances in vivo expression of hTNF-alpha in transduced melanoma cell line. Anticancer Res. 2001 Nov-Dec; 21(6A):4001-4.
Giermasz A, Grzela T, Nowis D, Makowski M, Czajka A, Stoklosa T, Lasek W, Dabrowsk A, Wiznerowicz M, Mackiewicz A, Jakóbisiak M. PMID: 11911283.
View in:
PubMed Mentions: Fields:
Translation:
HumansAnimalsCells
-
Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia. 2001 Apr; 15(4):613-20.
Gol b J, Zagozdzon R, Kaminski R, Kozar K, Gryska K, Izycki D, Mackiewicz A, Stoklosa T, Giermasz A, Lasek W, Jakóbisiak M. PMID: 11368364.
View in:
PubMed Mentions:
4 Fields:
Translation:
AnimalsCells
-
Antitumor activity of tributyrin in murine melanoma model. Cancer Lett. 2001 Mar 26; 164(2):143-8.
Giermasz A, Nowis D, Jalili A, Basak G, Marczak M, Makowski M, Czajka A, Mlynarczuk I, Hoser G, Stok osa T, Lewandowski S, Jakóbisiak M. PMID: 11179828.
View in:
PubMed Mentions:
4 Fields:
Translation:
HumansAnimalsCells
-
Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice. Neoplasma. 2001; 48(5):358-61.
Dabrowska A, Giermasz A, Golab J, Jakóbisiak M. PMID: 11845979.
View in:
PubMed Mentions:
2 Fields:
Translation:
AnimalsCells
-
Lovastatin and simvastatin are modulators of the proteasome. Int J Biochem Cell Biol. 2000 Sep; 32(9):957-65.
Wójcik C, Bury M, Stoklosa T, Giermasz A, Feleszko W, Mlynarczuk I, Pleban E, Basak G, Omura S, Jakóbisiak M. PMID: 11084375.
View in:
PubMed Mentions:
11 Fields:
Translation:
AnimalsCells
-
Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res. 2000 May; 6(5):2044-52.
Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, Giermasz A, Jakóbisiak M. PMID: 10815931.
View in:
PubMed Mentions:
32 Fields:
Translation:
AnimalsCells
-
Potentiation of the anti-tumour effects of Photofrin-based photodynamic therapy by localized treatment with G-CSF. Br J Cancer. 2000 Apr; 82(8):1485-91.
Golab J, Wilczynski G, Zagozdzon R, Stoklosa T, Dabrowska A, Rybczynska J, Wasik M, Machaj E, Olda T, Kozar K, Kaminski R, Giermasz A, Czajka A, Lasek W, Feleszko W, Jakóbisiak M. PMID: 10780531; PMCID: PMC2363378.
View in:
PubMed Mentions:
13 Fields:
Translation:
HumansAnimalsCells
-
Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice. Life Sci. 2000 Feb 18; 66(13):1223-30.
Golab J, Kozar K, Kaminski R, Czajka A, Marczak M, Switaj T, Giermasz A, Stoklosa T, Lasek W, Zagozdzon R, Mucha K, Jakóbisiak M. PMID: 10737417.
View in:
PubMed Mentions:
2 Fields:
Translation:
AnimalsCells
-
Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo. Oncol Rep. 2000 Jan-Feb; 7(1):177-81.
Golab J, Zagozdzon R, Kozar K, Kaminski R, Giermasz A, Stoklosa T, Lasek W, Jakobisiak M. PMID: 10601614.
View in:
PubMed Mentions:
4 Fields:
Translation:
AnimalsCells
-
Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice. Anticancer Res. 2000 Jan-Feb; 20(1A):391-4.
Dabrowska A, Giermasz A, Marczak M, Golab J, Jakóbisiak M. PMID: 10769685.
View in:
PubMed Mentions:
2 Fields:
Translation:
AnimalsCells
-
The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production. Cancer Lett. 1999 Dec 01; 147(1-2):67-75.
Zagozdzon R, Giermasz A, Golab J, Stoklosa T, Jalili A, Jakóbisiak M. PMID: 10660091.
View in:
PubMed Mentions:
2 Fields:
Translation:
AnimalsCells
-
Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice. Eur Cytokine Netw. 1999 Sep; 10(3):345-56.
Lasek W, Golab J, Maslinski W, Switaj T, Balkowiec EZ, Stoklosa T, Giermasz A, Malejczyk M, Jakóbisiak M. PMID: 10477391.
View in:
PubMed Mentions:
2 Fields:
Translation:
AnimalsCells
-
Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer. 1999 May 17; 81(4):560-7.
Feleszko W, Balkowiec EZ, Sieberth E, Marczak M, Dabrowska A, Giermasz A, Czajka A, Jakóbisiak M. PMID: 10225445.
View in:
PubMed Mentions:
20 Fields:
Translation:
AnimalsCells
-
Re: Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst. 1999 May 05; 91(9):804-6.
Dabrowska A, Golab J, Giermasz A, Marczak M, Jakóbisiak M. PMID: 10328115.
View in:
PubMed Mentions: Fields:
Translation:
HumansAnimalsCells
-
Inhibition of proteasome, apoptosis and sensitization to tumour necrosis factor alpha: do they always go together? Br J Cancer. 1999 Jan; 79(2):375-6.
Stoklosa T, Wójcik C, Golab J, Giermasz A, Wilk S. PMID: 9888486.
View in:
PubMed Mentions:
3 Fields:
Translation:
HumansAnimalsCells
-
Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int J Cancer. 1998 Aug 31; 77(5):720-7.
Zagozdzon R, Golab J, Stoklosa T, Giermasz A, Nowicka D, Feleszko W, Lasek W, Jakóbisiak M. PMID: 9688305.
View in:
PubMed Mentions:
7 Fields:
Translation:
AnimalsCells
-
G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice. Ann Oncol. 1998 Jan; 9(1):63-9.
Golab J, Stoklosa T, Zagozdzon R, Kaca A, Giermasz A, Pojda Z, Machaj E, Dabrowska A, Feleszko W, Lasek W, Iwan-Osiecka A, Jakóbisiak M. PMID: 9541685.
View in:
PubMed Mentions:
3 Fields:
Translation:
Animals
-
Granulocyte colony-stimulating factor demonstrates antitumor activity in melanoma model in mice. Neoplasma. 1998; 45(1):35-9.
Golab J, Zagozdzon R, Stoklosa T, Kaca A, Dabrowska A, Giermasz A, Feleszko W, Jakóbisiak M. PMID: 9605000.
View in:
PubMed Mentions:
1 Fields:
Translation:
AnimalsCells
-
Granulocyte-macrophage colony-stimulating factor potentiates antitumor activity of interleukin-12 in melanoma model in mice. Tumour Biol. 1998; 19(2):77-87.
Golab J, Stoklosa T, Zagozdzon R, Kaca A, Kulchitska LA, Feleszko W, Kawiak J, Hoser G, Glowacka E, Dabrowska A, Giermasz A, Lasek W, Jakóbisiak M. PMID: 9486559.
View in:
PubMed Mentions:
2 Fields:
Translation:
AnimalsCells
-
Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model. Anticancer Res. 1997 Nov-Dec; 17(6D):4493-8.
Zagozdzon R, Stoklosa T, Golab J, Giermasz A, Dabrowska A, Lasek W, Jakóbisiak M. PMID: 9494557.
View in:
PubMed Mentions:
2 Fields:
Translation:
Animals
-
Apoptosis induced in L1210 leukaemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome. Apoptosis. 1997; 2(5):455-62.
Wójcik C, Stoklosa T, Giermasz A, Golab J, Zagozdzon R, Kawiak J, Wilk S, Komar A, Kaca A, Malejczyk J, Jakóbisiak M. PMID: 14646528.
View in:
PubMed Mentions:
2 Fields:
-
Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results. Int J Cancer. 1996 May 03; 66(3):374-9.
Lasek W, Giermasz A, Kuc K, Wankowicz A, Feleszko W, Golab J, Zagozdzon R, Stoklosa T, Jakóbisiak M. PMID: 8621260.
View in:
PubMed Mentions:
4 Fields:
Translation:
AnimalsCells
-
Granulocyte-macrophage colony-stimulating factor accelerates growth of Lewis lung carcinoma in mice. Cancer Lett. 1996 Mar 29; 101(2):193-7.
Feleszko W, Giermasz A, Golatb J, Lasek W, Kuc K, Szperl M, Jakóbisiak M. PMID: 8620469.
View in:
PubMed Mentions: Fields:
Translation:
Animals
-
Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice. Oncology. 1996 Jan-Feb; 53(1):31-7.
Lasek W, Wankowicz A, Kuc K, Feleszko W, Giermasz A, Jakóbisiak M. PMID: 8570128.
View in:
PubMed Mentions:
4 Fields:
Translation:
HumansAnimals
-
Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice. Cancer Immunol Immunother. 1995 May; 40(5):315-21.
Lasek W, Wankowicz A, Kuc K, Feleszko W, Golab J, Giermasz A, Wiktor-Jedrzejczak W, Jakóbisiak M. PMID: 7600564.
View in:
PubMed Mentions:
7 Fields:
Translation:
AnimalsCells